Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Thomas Moehler, MD PhD, Magdalena Ruiz, MD MSc, Vicky Casey, Luana Margotto Soares, Fil Manuguid, Kriti Jindal, MS, Sari Heitner Enschede, MD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-135921

Published: 2020

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2007) 110 (11): 4825.

https://doi.org/10.1182/blood.V110.11.4825.4825

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Ingo G.H. Schmidt-Wolf, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Uwe Janssens, MD, Joerg Schubert, MD, Patrick Brueck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, Ph.D., Susanne Herz, Ph.D., Marie von Lilienfeld-Toal, M.D., Ralph Naumann, MD, Marcus Gorschlueter, MD, Axel Glasmacher, MD

Blood (2006) 108 (11): 3559.

https://doi.org/10.1182/blood.V108.11.3559.3559

Published: 2006

Journal Articles

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Ute Hegenbart, MD, Stefan O. Schonland, MD, Thomas Moehler, MD, Axel Benner, PhD, Sabine Gerull, MD, Martin Goerner, MD, Hans-Joerg Schaefer, MD, Gerlinde Egerer, MD, Peter Dreger, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD

Blood (2006) 108 (11): 3018.

https://doi.org/10.1182/blood.V108.11.3018.3018

Published: 2006

Journal Articles

Dynamic Contrast-Enhanced MRI Identifies a Distinct Group of Asymptomatic Myeloma Patients with Increased Bone Marrow Microcirculation.

Jens Hillengass, MD, Christian Zechmann, MD, Andreas Nadler, Stefan Delorme, MD, Axel Benner, Christiane Heiss, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Thomas Moehler, MD

Blood (2006) 108 (11): 5079.

https://doi.org/10.1182/blood.V108.11.5079.5079

Published: 2006

Journal Articles

Bone Marrow Microcirculation Parameter Amplitude A of Contrast-Enhanced Dynamic MRI Is a Prognostic Factor for Progressive Multiple Myeloma for Patients with Low Beta2-Microglobulin.

Jens Hillengass, MD, Klaus Wasser, MD, Axel Benner, Stefan Delorme, MD, Christian Zechmann, MD, Anthony D. Ho, Hartmut Goldschmidt, Thomas Moehler, MD

Blood (2005) 106 (11): 5062.

https://doi.org/10.1182/blood.V106.11.5062.5062

Published: 2005

Journal Articles

Non-Myeloablative Allogeneic Transplantation in Patients with Relapsed or Refractory Multiple Myeloma.

Sabine Gerull, MD, Ute Hegenbart, MD, Martin Goerner, MD, Axel Benner, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD

Blood (2004) 104 (11): 2759.

https://doi.org/10.1182/blood.V104.11.2759.2759

Published: 2004

NARROW

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Dynamic Contrast-Enhanced MRI Identifies a Distinct Group of Asymptomatic Myeloma Patients with Increased Bone Marrow Microcirculation.

Bone Marrow Microcirculation Parameter Amplitude A of Contrast-Enhanced Dynamic MRI Is a Prognostic Factor for Progressive Multiple Myeloma for Patients with Low Beta2-Microglobulin.

Non-Myeloablative Allogeneic Transplantation in Patients with Relapsed or Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Dynamic Contrast-Enhanced MRI Identifies a Distinct Group of Asymptomatic Myeloma Patients with Increased Bone Marrow Microcirculation.

Bone Marrow Microcirculation Parameter Amplitude A of Contrast-Enhanced Dynamic MRI Is a Prognostic Factor for Progressive Multiple Myeloma for Patients with Low Beta2-Microglobulin.

Non-Myeloablative Allogeneic Transplantation in Patients with Relapsed or Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only